Fastest-Growing Companies

America's fastest growing companies ranked by stock growth and state.

1 of 100
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Financials: Latest Results
Rank: 1
3-year average
Revenue Growth: 68%
Profit Growth: 279%
Total Return: 106%

In medical terminology, a bolus is a massive dose of a drug administered all at once. Jazz Pharmaceuticals has experienced a similar infusion of cash recently, thanks in large part to the success of its narcolepsy drug, Xyrem, which improves the quality of narcolepticsâÄô waking hours by helping them get a good nightâÄôs sleep.

With no market competition for Xyrem, the Dublin-based biopharmaceutical has been able to ratchet up its price twice this year. Acquisitions of Azur Pharma and EUSA Pharma in 2012 are also adding sales and reducing the companyâÄôs reliance on Xyrem. With EUSA, Jazz brought in Erwinaze, now the second-highest seller in its ensemble. The leukemia drug contributed more than 20% of the companyâÄôs first quarter revenue. --Shannon Green

Revenues ($ millions): 680
Net Income ($ millions): 304.3
Sector: Health Care
To qualify, a company-domestic or foreign-must be trading on a major U.S. stock exchange; report data in U.S. dollars; file quarterly reports with the SEC; have a minimum market... More